POTENTIATION OF CYTOTOXICITY OF KAPOSI'S SARCOMA RELATED TO IMMUNODEFICIENCY SYNDROME (AIDS) BY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


POTENTIATION OF CYTOTOXICITY OF KAPOSI'S SARCOMA RELATED TO IMMUNODEFICIENCY SYNDROME (AIDS) BY LIPOSOME ENCAPSULATED DOXORUBICIN (LED) (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A1483 1992. Unique Identifier : AIDSLINE ICDB/92684004
Masood R; Rahman A; Husain SR; Salahuddin SZ; Gill P; Dept. of Medicine, Norris Cancer Center, Univ. of Southern; California, Los Angeles, CA

Abstract: Kaposi's sarcoma is an independent criteria for the diagnosis of AIDS and develops in nearly 30% of all cases. Current chemotherapy regimens are associated with substantial toxicity, particularly bone marrow suppression, which, thus, limits their use in many patients. To develop new modalities of treatment, LED was prepared using cardiolipin, phosphatidyl choline, and cholesterol. The KS cells were exposed with varying concentrations of free doxorubicin (DOX) and LED and cell survival was determined after 24 hr. The IC50 with DOX was 750 ng/ml, whereas the IC50 with LED was only 7.5 ng/ml. Hence, KS cells are sensitized 100-fold by LED. The cellular uptake of drug in KS cells was followed from 1 to 4 hr. The DOX uptake with KS cells is fast and comes to a plateau after 1 hr, whereas with LED continued uptake up to 4 hr is seen. LED provides at least 3-fold higher drug uptake than DOX. This study demonstrates that LED may have the potential for an effective modality for the treatment of Kaposi's sarcoma.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Biological Transport Cardiolipins Cell Survival/DRUG EFFECTS Cholesterol Doxorubicin/ADMINISTRATION & DOSAGE/*PHARMACOLOGY Drug Carriers Human Kinetics Liposomes Phosphatidylcholines Sarcoma, Kaposi's/*DRUG THERAPY Tumor Cells, Cultured ABSTRACTKWDacquiredimmunodeficiencysyndrome/KWDcomplicationsbiologicaltransportcardiolipinscellsurvival/drugeffectscholesteroldoxorubicin/administration&dosage/KWDpharmacologydrugcarriershumankineticsliposomesphosphatidylcholinessarcoma,kaposi's/KWDdrugtherapytumorcells,culturedabstract
920830
M9281093

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .